Home    Back

Biv009    (DrugBank: -)

2 diseases
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia1
162Pemphigoid1

61. Autoimmune hemolytic anemia    [ 90 clinical trials,   72 drugs,   (DrugBank: 23 drugs),   19 drug target genes,   147 drug target pathways]
Searched query = "Autoimmune hemolytic anemia", "AIHA", "WAIHA", "Cold agglutinin disease", "CAD", "Paroxysmal cold hemoglobinuria", "MAIHA", "Evans syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 90 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02502903
(ClinicalTrials.gov)		July 13, 20157/7/2015Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated DisordersSafety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.Bullous Pemphigoid (BP);Cold Agglutinin Disease (CAD);Warm Autoimmune Hemolytic Anemia (WAIHA);End-stage Renal Disease (ESRD)Drug: BIV009;Other: PlaceboBioverativ, a Sanofi companyCelerion Clinical Research GmbH;Assign Data Management and Biostatistics GmbH;ABF Pharmaceutical Services GmbH;Quest Diagnostics;Covance Laboratories - Chantilly;PPD Laboratories - Virginia;Softworld Inc. - Cambridge, MAActive, not recruiting18 YearsN/AAll122Phase 1Austria

162. Pemphigoid    [ 70 clinical trials,   117 drugs,   (DrugBank: 46 drugs),   30 drug target genes,   128 drug target pathways]
Searched query = "Pemphigoid", "Epidermolysis bullosa acquisita"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 70 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02502903
(ClinicalTrials.gov)		July 13, 20157/7/2015Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated DisordersSafety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.Bullous Pemphigoid (BP);Cold Agglutinin Disease (CAD);Warm Autoimmune Hemolytic Anemia (WAIHA);End-stage Renal Disease (ESRD)Drug: BIV009;Other: PlaceboBioverativ, a Sanofi companyCelerion Clinical Research GmbH;Assign Data Management and Biostatistics GmbH;ABF Pharmaceutical Services GmbH;Quest Diagnostics;Covance Laboratories - Chantilly;PPD Laboratories - Virginia;Softworld Inc. - Cambridge, MAActive, not recruiting18 YearsN/AAll122Phase 1Austria